Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tomudex

(Raltitrexed)

Phase 2Small molecule

NNanjing Chia-tai Tianqing Pharmaceutical

Raltitrexed is used to treat certain types of cancer, particularly colorectal cancer. It works by stopping cancer cells from growing and dividing.[1] Tomudex is currently being investigated across 4 indications[3], with its most advanced program in Phase 2.[1]

Tomudex is one of 70 small molecule programs targeting Rectal Adenocarcinoma. It is currently in Phase 2.

4

Indications

32

Total Trials

3

Active Trials

69

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rectal AdenocarcinomaUnknown

TreatmentNot yet recruiting

Hypofractionated RadiotherapyRecruiting

FruquintinibRecruiting

Rectal AdenocarcinomaPreclinical

Unknown

TreatmentPhase 2

Not yet recruiting

Hypofractionated RadiotherapyPhase 2

Recruiting

FruquintinibPhase 2

Recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Tomudex

NNanjing Chia-tai Tianqing Pharmaceutical

Dexilant

Emtriva

Alfenta

Jazz Pharmaceuticals

Lamprene

Foscavir

CClinigen, Inc.

Lotemax

Norpramin

VValidus Pharmaceuticals

Barhemsys

Tibotec Pharmaceuticals, Ireland

Clomid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Treatment

NCT06652412

Clinical

Trials by Indication[1]

Colorectal Cancer11 trials

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

Unknown status·FFudan University·Phase 2·NCT03823079·50 enrolled

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Unknown status·JJiangsu Cancer Institute & Hospital·Phase 2·NCT03126071·100 enrolled

Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer

Unknown status·FFudan University·Phase 2·NCT02618356·82 enrolled

Show 8 more trials

Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients

Unknown status·—·Phase 2·NCT03053167·100 enrolled

Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Unknown status·MMedical Research Council·Phase 3·NCT00002893·900 enrolled

A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer

Unknown status·JJiangsu Cancer Institute & Hospital·Phase 2·NCT04241731·50 enrolled

Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00002828

Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases

Unknown status·NNanjing Chia-tai Tianqing Pharmaceutical·Phase 4·NCT01959061·320 enrolled

Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients

Unknown status·FFudan University·Phase 2·NCT02376452·100 enrolled

Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure

Completed·CCentre Georges Francois Leclerc·Phase 2·NCT01348412·31 enrolled

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Unknown status·—·Phase 1/2·NCT05426811·50 enrolled

Malignant Mesothelioma2 trials

Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00004920·256 enrolled

Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00004254·25 enrolled

Liver Metastases1 trial

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

Unknown status·FFudan University·Phase 2·NCT05435313·39 enrolled

Esophageal Cancer1 trial

A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer

Unknown status·TThe First People's Hospital of Lianyungang·Phase 2·NCT01732380·108 enrolled

Head and Neck Squamous Cell Cancer1 trial

Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer

Unknown status·JJiangsu Cancer Institute & Hospital·Phase 3·NCT02485548·120 enrolled

16 more indications

Fruquintinib1 trial

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

Recruiting·MMeng Qiu·Phase 2·NCT06427005·66 enrolled

First-line Treatment1 trial

RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study)

Unknown status·SShenzhen People's Hospital·Phase 2·NCT03813641·100 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Completed·CChinese Academy of Medical Sciences·Phase 2·NCT03083613·41 enrolled

Patients With Advanced Solid Tumors1 trial

Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00002902

Pancreatic Cancer1 trial

The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer

Unknown status·FFudan University·Phase 2·NCT04581876·120 enrolled

Refractory Solid Tumors1 trial

Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors

Completed·FFox Chase Cancer Center·Phase 1·NCT00003109·39 enrolled

Metastatic Colorectal Cancer1 trial

SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05160896·90 enrolled

Gastric Cancer1 trial

Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection

Unknown status·ZZhongnan Hospital·Phase 2·NCT03392103·48 enrolled

Locally-advanced Rectal Cancer1 trial

Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly

Completed·CChinese Academy of Medical Sciences·Phase 2·NCT02992886·68 enrolled

Squamous Cell Carcinoma1 trial

Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus

Unknown status·HHuai'an First People's Hospital·Phase 2·NCT03585530·32 enrolled

Acute Leukemia1 trial

Raltitrexed in Treating Children With Refractory Acute Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003528·30 enrolled

Rectal Cancer1 trial

Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer

Completed·NNational Cancer Institute, Naples·Phase 2·NCT01481545·62 enrolled

Treatment1 trial

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

Not yet recruiting·FFudan University·Phase 2·NCT06652412·124 enrolled

Older Patients1 trial

Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC.

Unknown status·TThe First Affiliated Hospital of Dalian Medical University·Phase 4·NCT03196843·202 enrolled

Hypofractionated Radiotherapy1 trial

The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT05628038·93 enrolled

Unspecified1 trial

Raltitrexed in HIPEC

Completed·FFudan University·Phase 1·NCT04761185·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 32 trial records for Raltitrexed. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Raltitrexed compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Raltitrexed. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanjing Chia-tai Tianqing Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Thymidylate Synthase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNanjing Chia-tai Tianqing Pharmaceutical

Related News